companiesandmarkets.com

Return to Report | Print

Premium Company Profile Novavax

http://www.companiesandmarkets.com/Summary-Company-Profile/premium-company-profile-novavax-41356.asp

Report Summary

Introduction

Novavax is a biopharmaceutical company focused on developing vaccines against the H5N1, H9N2 and other subtypes of avian influenza with pandemic potential as well as vaccines that protect against seasonal influenza. These vaccines leverage the company's virus-like particle (VLP) platform technology, Novasome adjuvants and unique production technology.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Highlights

    Novavax is focused on creating vaccines for a range of infectious diseases. The company's Estrasorb is the first topical emulsion for estrogen therapy approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause. The company also markets Gynodiol used for estrogen replacement therapy.

    The company's total revenues declined at a CAGR of 25% during 2002-2006, from $15 million to $5 million. The major reason for revenue decline was the decreasing product sales. Product sales of the company decreased at a CAGR of 34% during 2002-2006, from $13 million to $3 million.

    The company's total revenues would increase at a CAGR of 12% during 2006-2010 from $5 million to $8 million. The company's biggest contributor to revenue growth out to 2010 will be revenues from contract research and development.

    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    TABLE OF CONTENTS
    Overview 1
    Catalyst 1
    Summary 1
    Company Structure 7
    Company Overview and Key Facts 7
    Business Description 8
    History 10
    Company Financials 12
    Stock Market Performance 12
    P&L 13
    Balance Sheet 16
    Cash Flow 16
    Business Segment Performance 17
    Products & Services 19
    Marketed Products 19
    Pipeline Products 20
    AC Forecast Product Sales 21
    Competitors and Strategic Business Relationships 23
    Key Competitors 23
    Key Suppliers 23
    Key Clients 24
    Shareholding Structure 25
    Strategy 26
    Company View 26
    Corporate Strategy 26
    SWOT Analysis 28
    Overview 28
    Strengths 29
    Weaknesses 30
    Opportunities 31
    Threats 32
    Value Chain Analysis 33
    Overview 33
    Discovery and Product Development 33
    Manufacturing 34
    Scorecard 35
    Overview 35
    Scorecard Analysis 36
    Key Employees 37
    List of Key Employees 37
    Key Employee Biographies 38
    Financial and Operational Overview 42
    Financial and Operational Overview 42
    Key Industry Specific Ratios 44
    APPENDIX 45
    Ask the analyst 45
    Datamonitor consulting 45
    Disclaimer 45


    TABLE OF FIGURES
    Figure 1: Novavax - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 14
    Figure 2: Novavax - Key Strategic Revenues, 2002-2006 ($ Mn) 18
    Figure 2: Novavax - Key Strategic Revenues, 2006-2010 ($ Mn) 22


    TABLE OF TABLES
    Table 1: Novavax - Key Facts 7
    Table 2: Novavax - Year-End Share Price and Market Capitalization, 2002-2006 ($) 12
    Table 3: Novavax - Key Events Impacting Share Price Performance 12
    Table 4: Novavax - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
    Table 5: Novavax - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 15
    Table 6: Novavax - Balance Sheet, 2002-2006 ($ Mn) 16
    Table 7: Novavax - Cash Flow, 2002-2006 ($ Mn) 16
    Table 8: Novavax - Revenue Breakdown by Division, 2002-2006 ($ Mn) 17
    Table 9: Novavax - Marketed Products 19
    Table 10: Novavax - Collaboration Products 20
    Table 11: Novavax - Forecast Sales, 2006-2010 ($ Mn) 21
    Table 12: Novavax - Key Competitors 23
    Table 13: Novavax - Key Clients 24
    Table 14: Novavax – Key Shareholders 25
    Table 15: Novavax - SWOT Analysis Summary 28
    Table 16: Novavax – Value Chain Analysis 33
    Table 17: Novavax - Scorecard 35
    Table 18: Novavax - Key Employees 37
    Table 19: Novavax - Financial and Operational Overview 42
    Table 20: Novavax - Key Industry Specific Ratios 44